

Nordic walking to improve functional exercise capacity and daily physical activities in chronic obstructive pulmonary disease (COPD)

Submission date 11/03/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 21/04/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/04/2009	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof O C Burghuber

Contact details
Ludwig Boltzmann Institute for COPD
Sanatoriumstrasse 2
Vienna
Austria
1140

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NA

Study information

Scientific Title

Nordic walking to improve functional exercise capacity and daily physical activities in chronic obstructive pulmonary disease (COPD): a randomised controlled trial

Study objectives

The aim of the present study was to determine whether and to what extent Nordic walking is feasible in increasing functional exercise capacity in patients with chronic obstructive pulmonary disease (COPD). Additionally, we aimed to determine short- and long-term effects of Nordic walking on daily physical activity level, exercise performance and mood status in patients with COPD.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of Vienna (Ethikkommission der Stadt Wien), approved on 15/03/2006 (ref: EK 06-058-VK)

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

The participants were randomised to either the intervention or control group:

Intervention group: 12 weeks outdoor Nordic walking exercise programme (1 hour per session, 3 times/week)

Control group: no exercise intervention

Patients randomised to the intervention group trained 3 times a week for 1 hour at recommended 75% of their initial maximum heart frequency obtained during initial maximum exercise test. In addition, the participants in the intervention group attended 1 hour/week

educational sessions on pulmonary pathophysiology, management of breathlessness and exacerbations, clearance of pulmonary secretions, smoking cessation, medication and nutrition.

The control group received 1 hour/month educational sessions.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Functional exercise capacity, assessed using the six minute walking test (6MWT).

All primary and secondary outcome measures will be assessed at baseline and after 3, 6, and 9 month.

Secondary outcome measures

1. Daily physical activities, assessed using a tri-axial accelerometer (DynaPort® Activity Monitor; McRoberts BV, Netherlands)
2. Exercise-induced dyspnoea, assessed using the modified Borg Dyspnoea Scale
3. Mood status, assessed using the Hospital Anxiety and Depression Scale (HADS)

All primary and secondary outcome measures will be assessed at baseline and after 3, 6, and 9 month.

Overall study start date

01/03/2006

Completion date

01/03/2007

Eligibility**Key inclusion criteria**

1. Both males and females, age >18 years
2. Stable COPD (no infection or exacerbation for at least 12 weeks)
3. Absence of severe and/or unstable cardiac diseases (myocardial infarction within the last 6 month, cardiac arrhythmia Lown classification >IIIb, as shown by electrocardiogram during rest and maximal exercise test)
4. Absence of other pathologic conditions that could impair daily physical activities (cerebrovascular diseases, rheumatism, symptomatic osteoporosis and others)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

60

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/03/2006

Date of final enrolment

01/03/2007

Locations

Countries of recruitment

Austria

Study participating centre

Ludwig Boltzmann Institute for COPD

Vienna

Austria

1140

Sponsor information

Organisation

Ludwig Boltzmann Institute for COPD (Ludwig Boltzmann Institut für COPD) (Austria)

Sponsor details

Sanatoriumstrasse 2

Vienna

Austria

1140

Sponsor type

Research organisation

Website

<http://www.lbg.ac.at>

ROR

<https://ror.org/01tf5aq62>

Funder(s)

Funder type

Research organisation

Funder Name

Ludwig Boltzmann Institute for COPD (Ludwig Boltzmann Institut für COPD) (Austria) -

<http://www.lbg.ac.at>

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration